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Peptides are important natural molecules that possess functions as diverse as antibiotics,
toxins, venoms and hormones, for example. However, whilst these peptides have useful
properties, there are many targets and pathways that are not addressed through the
activities of natural peptidic compounds. In these circumstances, directed evolution
techniques, such as phage display, have been developed to sample the diverse chemical
and structural repertoire of small peptides for useful means. In this review, we consider
recent concepts that relate peptide structure to drug-like attributes and how these
are incorporated within display technologies to deliver peptides de novo with valuable
pharmaceutical properties.
Keywords: directed evolution, display systems, peptide drug discovery, peptides and derivatives, stability,
non-natural amino acids, cyclic peptides
Peptides have traditionally been considered a poor choice for drug candidates owing to their low
bioavailability, susceptibility to proteolysis, and rapid clearance (Craik et al., 2013; Otvos and
Wade, 2014). Nevertheless, peptides are powerful natural mediators of biological processes (Kastin,
2006) and over 60 peptide products have been approved by the FDA with global sales estimated
at US$14.7b in 2011 (seven of which have been generating sales in excess of US$0.5b) with a
further 140 in clinical development (Reichart, 2010; Hamzeh-Mivehroud et al., 2013; Kaspar and
Reichert, 2013). As a drug modality, peptides, and peptidomimetics occupy the interface between
small molecule and larger biological drugs with the potential to have the specificity of antibodies
and the bioavailability of small molecules. Yet, although this prospect has yet to be fully realized,
there has been significant recent progress in this direction (Craik et al., 2013; Otvos and Wade,
2014). Peptides provide the researcher with interesting options for discovery, optimization, and
manufacture as they can be synthesized chemically or expressed by recombinant systems. For
example, recombinant methods of discovery, such as directed evolution display systems, have
isolated novel sequences in addition to those found in nature. Additionally, chemical methods of
improvement can be employed to optimize stability, affinity, or bioavailability. In this short review,
we will briefly describe biological methods for discovering new peptide entities and the chemical
methods that are implemented to improve pharmacological properties.
Early combinatorial peptide synthesis methods described synthesis of hexamer peptide libraries
on pins or beads, but chemical synthesis methods have since improved significantly in scale and
coupling efficiencies (Geysen and Mason, 1993; Lam et al., 1993; Breitling et al., 2009). However,
recombinant display systems are capable of screening libraries that are orders of magnitude larger.
These display methods are based upon the principle that each peptide maintains a link between
itself and the nucleic acid code from which it was expressed so that it can be identified ultimately
from a diverse population by nucleic acid sequencing, following cycles of binding, washing, and
enrichment (Figure 1A). This genotype-phenotype link is exhibited by displaying the peptide with
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FIGURE 1 | (A) Overview of the process of directed evolution. Combinatorial
genetic libraries are created through mutagenesis, then transcribed and
translated into peptides which retain a physical link with their encoding genetic
information. Application of selection pressure, such as cycles of washing,
amplification and further selection, enrich the binding clones within the
population. Ultimately, binding peptides are identified through sequencing of
the genetic material. (B) Diagram showing different formats of display where
the peptide is expressed on the surface of a yeast or bacterium (i)
(yeast/bacterial display); or a bacteriophage (ii) (phage display); or in complex
with a ribosome (iii) (ribosome display); linked to RNA through puromycin (iv)
(mRNA display); or bound to DNA through the cis activity of a DNA binding
protein (v) (CIS display). In all these examples the peptide is associated with its
coding sequence maintaining a genotype-phenotype link and is free to
associate to its target (adapted from Ullman et al., 2011).
its genetic material encapsulated in a virus particle (e.g., phage
display), or on the surface of a cell which contains the genetic
information (e.g., yeast or bacterial display) or directly linked to
the nucleic acid through non-covalent or covalent means (e.g.,
CIS display, mRNA display, and ribosome display) (Figure 1B;
Ullman et al., 2011).
Cellular display approaches require cells to be transformed,
a process that delivers the coding sequence of the peptide
into a host cell for expression and display. In phage display,
filamentous or T7 lytic bacteriophages are produced with the
peptide expressed in fusion with a viral coat protein (usually
pIII or pVIII in the case of M13). Within a diverse library, each
phage particle carries a different peptide clone. This library is
“panned” to select binding peptides amongst the population,
panning conditions being balanced so that stringency is sufficient
to isolate rare high affinity peptides from a background of poor or
non-binding members (Smith and Petrenko, 1997; Sidhu et al.,
2000; Hoogenboom, 2005; Levin andWeiss, 2006; Sergeeva et al.,
2006; Krumpe and Mori, 2007; Hamzeh-Mivehroud et al., 2013).
Molecules isolated by phage display are now just reaching the
market, for example Peginesatide, a novel PEGylated peptide.
Peginesatide acts as an agonist of the erythropoietin receptor and
was approved by the FDA for the treatment of anemia due to
chronic kidney disease in adult patients on dialysis (Wrighton
et al., 1996; Macdougall et al., 2009; Reichart, 2010). Although
effective, Peginesatide has now been withdrawn due to safety
concerns. Phage display has been used successfully for in vivo
panning (“biopanning”) in animal and human subjects to isolate
tissue-specific peptides and those that can transgress biological
barriers such as the skin, blood brain barrier, intestinal tract, and
cell membrane (Arap et al., 2002; Frenkel and Solomon, 2002;
Gao et al., 2002; Duerr et al., 2004; Chen et al., 2006; Sergeeva
et al., 2006; Giordano et al., 2010). Yeast and bacterial display
are technically related methods where peptides or proteins can
be expressed on the surface of cells in fusion with Aga2p
(yeast) or bacterial flagellin, outer membrane proteins, such
as OmpA, or albumin binding protein and XM’ sequence of
staphylococcal protein A followed by affinity based cell-sorting
methods (Daugherty, 2007; Gai and Wittrup, 2007; Rockberg
et al., 2008).
Cell-free methods of peptide display avoid the need for
transformation and therefore are not bound by the practical
limitations of this procedure [typically up to 1010 clones for phage
although 1012 has been reported (Sidhu et al., 2000)], but can
reach a theoretical diversity of 1014 clones. Therefore, cell-free
methods potentially allow greater coverage of the sequence space.
These methods use the transcription and translation machinery
extracted from prokaryotic or eukaryotic cell lysates. In ribosome
display, ribosomes are stalled on the mRNA template through
the absence of a stop codon and the nascent peptide remains
in a complex with the ribosomes; a C-terminal peptide spacer
facilitates correct folding of the displayed polypeptide free from
steric hindrance by the ribosomal tunnel (Mattheakis et al.,
1994; Hanes and Plückthun, 1997; Douthwaite and Jackson,
2012). A related technique, mRNA display, differentiates itself
from ribosome display by the formation of a covalent link
between the template and the expressed peptide via puromycin.
Puromycin is carried on a DNA primer appended to the mRNA
template andmimics amino-acyl tRNA, binding covalently to the
nascent peptide as a result of the peptidyl transferase activity
of the ribosome (Nemoto et al., 1997; Roberts and Szostak,
1997; Douthwaite and Jackson, 2012). The RNA based systems
can be very sensitive to RNAse degradation and reconstituted
transcription translation systems have been employed to reduce
this effect, for example the PURE system (Shimizu et al.,
2001, 2005). DNA based cell-free systems such as, CIS display,
which harnesses the ability of a DNA-binding protein (RepA)
that exclusively binds back to its encoding template, offer the
advantage of speed, ease of use, and template stability over
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RNA (Odegrip et al., 2004; Eldridge et al., 2009; Patel et al.,
2013).
These aforementioned display systems enable vast libraries
to be screened based upon natural L-amino acids. However, in
order to drive efficacy, non-natural additions may be required.
In this respect we can gain insight from natural solutions. An
exemplar of an effective natural peptide drug is the macrocycle
cyclosporin A (CsA; Figure 2A). Originally isolated from the
fungus Tolypocladium inflatum it has been intensively studied
to understand the correlation between structural features and
pharmaceutically relevant properties (Loosli et al., 1985; Kessler
et al., 1990; Ko and Dalvit, 1992; Jin and Harrison, 2002).
These studies have revealed four key features responsible for
CsA’s cell permeability, serum stability, and oral bioavailability: a
cyclic backbone; incorporation of seven N-methyl groups; four
intramolecular hydrogen bond donors; incorporation of three
non-natural amino acid. Thus, CsA exhibits exquisite drug-like
properties despite violating medicinal chemistry’s traditional rule
of 5: No more than 5 hydrogen bond donors and 10 acceptors,
a molecular mass of less than 500Da, and a logP coefficient no
higher than 5 (Lipinski et al., 2001).
Investigations into other natural products and synthetic
peptide libraries have further highlighted the importance of
cyclisation and N-methylation for pharmacological properties
to the extent that these attributes reduce flexibility and favor
resistance to proteolysis, and provide a capacity to permeate
biological membranes through a reduction of the number of
amide hydrogen bond donors through N-methylation (Biron
et al., 2008; White et al., 2011). In addition, both cyclisation
and N-methylation support the formation of intramolecular
hydrogen bonds which further decreases flexibility and solvation
(Biron et al., 2008; White et al., 2011). Interestingly, most studies
of passive membrane perfusion by cyclic peptide libraries have
demonstrated that the impact of N-methylation on membrane
permeability was highly position dependent and not necessary
correlated with increasing N-methyl content (Biron et al., 2008;
White et al., 2011). Instead, optimal N-methylation patterns
favored conformations with reduced hydrogen bonding potential
for solvation by water, therefore reducing the desolvation of
the peptide before entering the membrane while simultaneously
concealing the hydrophilic backbone from the membrane
environment. Furthermore, it was established for CsA that
passive transcellular absorption might be a general characteristic
of a macrocycle that can assume multiple interconverting
conformations between the aqueous environment and the
lipophilic environment of the membrane (Bockus et al., 2013;
Wang et al., 2015). Finally, it is generally accepted that flexible
molecules face a higher entropic barrier upon binding to their
target than restrained molecules and often have lower affinity
than cyclic counterparts. The same effect might influence the
translocation of molecules from the highly mobile aqueous phase
to the reduced entropic environment of the membrane (Bockus
et al., 2013). Indeed, Veber et al. have shown that the number
of rotatable bonds is a better predictor of bioavailability than
molecular weight. These findings have helped to drive new
thinking and interest in designing novel molecules that occupy
the chemical space beyond the borders dictated by the Lipinski
rules of 5 (Veber et al., 2002). For macrocyles a recent study
highlighted an increase of clinical candidates administered by
oral routes (43%) compared to already registered drugs (28%).
In the subgroup of cyclic peptides CsA is currently the only oral
prescribed drug. However, 3 out of 11 cyclic peptides in trials
have biophysical properties similar to CsA and are tested for oral
applications (Giordanetto and Kihlberg, 2014).
Non-standard natural product peptides have provided
excellent leads for drug discovery in the field of antibiotics.
However, most of these peptides are synthesized by non-
ribosomal peptide synthetases, as is CsA. Although these
modifications can be synthesized chemically, the capacity of
molecular evolution methods in biological systems to generate
libraries of trillions of peptides is extremely attractive (Ullman
et al., 2011). Approaches to reengineer the complex gene cluster
involved in the synthesis of such peptides has proved to be
very challenging, however, several modifications have been
made to molecular display technologies to produce peptides
incorporating such features. These technologies can be broadly
classified into methodologies that are based on the incorporation
of non-natural amino acids and those that are based on
post-translational modification of encoded peptides.
IMPROVING PHARMACOLOGICAL
PROPERTIES OF PEPTIDES BY
POST-TRANSLATIONAL MODIFICATION
The first post-translational modification of a genetically encoded
phage peptide library involved cyclisation through disulphide-
bridge formation in which two invariant cysteine residues
flanked a random amino acid sequence (Figure 2E). Such cyclic
peptides had between 100 and 1000 fold higher affinities than
linear peptides isolated for the same target (O’Neil et al.,
1992; McLafferty et al., 1993), yet the sensitivity of the bond
to reducing environments encouraged the development of
chemistry-based cyclisation methods to obtain redox insensitive
macrocyles. For example, a modification of mRNA display based
on disuccinimidyl glutarate, which cross-linked the N-terminus
and an internal lysine sidechain (Figure 2G) to identify a cyclic
peptide from a trillion member library that bound to Gαi1 with
high affinity (Ki = 2 nM; Millward et al., 2005). The cyclic
peptide showed 15-fold improved affinity and 2.5-fold improved
proteolytic stability compared to the linear motif (Millward et al.,
2007).
The concept of using organic chemistry based cyclisation
methods to improve the properties of DNA encoded peptides
was further advanced by installing an activated aryl (tris-
(bromomethyl)benzene) to crosslink phage-displayed peptide
libraries containing three invariant cysteines into bi-cyclic
peptides (termed “bicycle”; Figure 2F; Heinis et al., 2009).
Selection with phage display against human plasma kallikrein
yielded specific inhibitors in the mid nM range which could be
further improved by affinity maturation to IC50 1.7 nM. The
linear analogs did not show any inhibition at up to 10µM,
thereby underlining the importance of the cyclic structure of the
peptide. The high specificity for human over mouse kallikrein
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FIGURE 2 | (A) Structure of CsA; (B–D) Incorporation of non-natural amino acids in peptide display systems: (B) Examples for the wide scope of non-natural amino
acids that can be included in display systems e.g., from left to right, D-tyrosine, N-Methyl-L-alanine, (S)-2-amino-4-azidobutanoic acid, (S)-2-aminohex-5-ynoic acid,
(S)-2-amino-3,3-dimethylbutanoic acid; (C) Incorporation of 4-selenalysine allows the formation of a lantipeptide with a cysteine residue; (D) Incorporation of amino
acids with a chloroacetylated N terminus allows the formation of thioether bond with a downstream cysteine. (E–G): Posttranslational modifications in peptide display
systems: (E) Formation of a cyclic peptide via a disulphide bond; (F) Formation of a cyclic peptide by cross linking two or three cysteine residues with activated aryls,
e.g., tris-(bromomethyl)benzene; (G) Formation of a cyclic peptide by cross linking the N terminus with a downstream lysine via disuccinimidyl glutarate.
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and other proteases was reasoned to be a result of the large
interaction interface between bicyclic peptide and target, a
potential advantage over mono-cyclic peptides (Heinis et al.,
2009). Activated aryls have been also used in the selection of
monocyclic peptides expressed by mRNA display (Schlippe et al.,
2012).
Post-translational modifications to improve pharmacological
properties of displayed peptides can also be introduced
enzymatically. Several approaches have been described in the
literature, e.g., the introduction of azoline moieties in peptide
backbones (Goto et al., 2014) or head-to-tail cyclisation via
an split-intein approach within cells using phenotype-based
selection rather than display. Kritzer et al. used this approach
to select candidates from a cyclic octamer peptide library, which
were able to rescue a yeast model of α-synuclein toxicity and
able to prevent neuron loss in a C. elegans model. Although
the use of a yeast platform limits the available library size, it
allows selection based on phenotype which has the advantage that
candidates are selected for efficacy rather than affinity and toxic
sequences are avoided (Kritzer et al., 2009). Yeast have also been
reprogrammed for the incorporation of non-natural amino acids
through orthologous amino acyl tRNA synthetase/tRNA pairs
(Chin, 2011). Recently, sidechain-to-tail cyclization through
ligation of 1,3- or 1,2-aminothiol functionalities within non-
natural amino acids and the C-terminus has been reported
enabling the isolation of improved streptavidin binding peptides
from a 144-member library produced inside cells (Frost et al.,
2015).
IMPROVING PHARMACOLOGICAL
PROPERTIES OF PEPTIDES BY
INCORPORATION OF NON-NATURAL
AMINO ACIDS
Two major routes have been explored to express peptides
with non-natural amino acids: Firstly, exploiting the ability of
native aminoacyl-tRNA synthetases to mischarge tRNAs, and
secondly performing genetic reprogramming via engineered
aminoacyl-tRNA synthetases. Both serve the goal of enhancing
pharmacokinetic parameters either by offering functionalized
groups for cyclisation or incorporation of elements that favor cell
permeability (e.g., N-methylation) or protease resistance.
Although, orthogonal aminoacyl-tRNAs and ribosomes have
been engineered within cells (Rackham and Chin, 2005), a
favored method of introducing non-natural amino acids is to
use cell-free in vitro transcription translation systems which
offer greater flexibility and library capacity. Szostak’s group
studied the ability of wildtype aminoacyl-tRNA synthetases to
mischarge tRNAs in situ with non-natural amino acids or the
use of reconstituted cell-free transcription translation mixtures
(Hartman et al., 2007; Schlippe et al., 2012). In total, over
50 substrates were found to be compatible with the in vitro
expression system leading to ribosomal synthesis of a 15-mer
peptide containing 13 non-natural amino acids. Although, most
structures of these substrates were close analogs to their cognate
amino acids, some included interesting functional groups as
halo-aryl, alkene, azide and tert-butyl groups (Figure 2B).
Although successful incorporation of N-methylated amino acids
was possible, the yields obtained were low. This was attributed
to the inefficiency of wildtype aminoacyl-tRNA synthetases to
mischarge tRNAs rather than the ribosomal incorporation of
such mischarged tRNAs into the nascent peptide chain. It was
feasible to overcome this limitation by supplementation of the
in vitro expression system with purified pre-charged tRNAs that
had previously been methylated by chemical means (Subtelny
et al., 2008, 2011).
These advances were applied to mRNA display for the
selection of cyclic peptides containing non-natural amino acids.
In the following study, a RNA library encoded random 10-
mer peptides where 12 of the 20 proteinogenic amino acids
were replaced by non-natural amino acids. The random region
was flanked by two constant cysteine residues which were used
to cyclise the peptide via the activated aryl α,α′-Dibromo-m-
xylene. Selection against thrombin yielded two peptides of low
nanomolar affinity in which cyclisation and incorporation of
non-natural amino acids was required for binding to thrombin.
This work exemplified the combination of both incorporation
of non-natural amino acids and postranslational modification,
however yet doesn’t address the advantages in respect of
proteolytic stability or oral bioavailability by incorporation of the
non-natural amino acids (Schlippe et al., 2012).
The added functionality which can be introduced by
incorporation of non-natural amino acids can also be used to
cyclise peptides directly. 4-selenalysine can be used as substrate
for lysine in an in vitro expression system and treated with
hydrogen peroxide for oxidative elimination of the seleno
moiety. The resulting dehydroalanine can subsequently react
with cysteine to form a lantipeptide via a stable thioether bond
(Figure 2C; Seebeck et al., 2011). The approach was applied
to select lantipeptides from an mRNA encoded peptide library
against Sortase A. Several lantipeptides could be identified,
albeit with low µM affinities and the stereochemistry of the
thioether bond had to be confirmed by synthesizing potential
isomers (Hofmann et al., 2012). Natural lantipeptides represent
an interesting class of macrocyclic modulators produced by a
range of Gram-positive bacteria and are often characterized
by antibacterial activities (Knerr and van der Donk, 2012).
In future, therapeutic peptides might also be cyclized by
the incorporation of dithiol amino acids which reduce the
complexity of synthesizing disulphide rich sequences and have
been demonstrated to significantly improve the activity of
parental peptides that possess –CC- motifs. However, this has yet
to be translated to biological systems (Chen et al., 2014).
An alternative to mischarge tRNAs with native aminoacyl
tRNA synthetases enzymes has been developed based on
flexizymes, a group of ribozymes that were engineered to
aminoacylate tRNAs. These flexizymes were developed to have
a low specificity toward the discriminatory nucleotides of a
particular tRNA and, therefore, accept a broad spectrum of
tRNA’s as substrates. Three main flexizymes have been produced
to recognize different leaving groups on activated amino acids
leading to improved charging of the tRNAs with the non-
natural amino acids based on the properties of the side chain.
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Orthogonal tRNAs, not recognized by wild type amino acyl
tRNA synthesases, are used in place of native tRNAs and
are accepted by the ribosome as substrates. Therefore, the
problematic incorporation of competing proteinogenic amino
acids during translation can be avoided. The generated non-
natural amino acid charged tRNAs can then be added to an
optimized in vitro expression system to fill codons within the
genetic code that have been left vacant by withdrawing specific
amino acids and their cognate aminoacyl-tRNA synthetases,
therefore “reprogramming” the codon to the new components
(Figures 2B,D; Ohta et al., 2007; Ohuchi et al., 2007; Xiao et al.,
2008; Goto et al., 2011; Reid et al., 2012). This has recently been
reviewed elsewhere (Passioura et al., 2014).
DISPLAY INDEPENDENT APPROACHES
TO ENHANCE BIOAVAILABILITY
So far this report has focused on molecular display technologies
which incorporate non-natural amino acids or post-translational
modifications prior to selection so that compounds can
be selected for affinity whilst incorporating elements to
improve biophysical and biological properties. In theory, the
bioavailability of a compound can be addressed following the
isolation of a binder, however, in practice this has proven to
be difficult. Conformational constrains or modifications that
improve bioavailability often negatively affect the affinity with the
exception of peptides in stable secondary structures. In particular
the modification of α-helices with hydrocarbon staples has been
shown to benefit both proteolytic stability and cell permeability.
Although this approach is not always successful, attrition rates
seem to be low if detailed structural data is available (Cromm
et al., 2015). Similar methods have also been applied to β-turn
structures (Obrecht et al., 2012).
A further variation presents the use of stable mini-scaffolds
that are known to have good bioavailability but are still
amendable to chemical synthesis. For example, cyclotides are
small head-to-tail cyclised disulfide rich peptides, which have
the potential to reach intracellular targets (Greenwood et al.,
2007). These scaffolds can be used as hosts for grafted active
sequences (Gould et al., 2011). Recently, recombinant expression
of cyclotides in yeast by a split-intein approach coupled to
a phenotypic screen has been developed thereby opening the
doors to screen genetically encoded cyclotide-based libraries in
eukaryotic cells (Jagadish et al., 2015).
FUTURE PERSPECTIVES
Methods tomodify natural peptides and those discovered de novo
by man using directed evolution have generated peptidic ligands
with improved properties, such as high affinity, excellent target
specificity and good plasma stability; additional modifications
can also provide pharmacological features to extend in vivo
half-life, if necessary. Future developments may ultimately
produce peptides that can be delivered orally, transverse the
blood brain barrier or access intracellular targets. The selectivity
of peptides, their rapid clearance by kidney filtration and
capacity for chemical modification are particularly beneficial for
molecular imaging applications and, potentially, for delivering
toxic payloads as peptide drug conjugates. In terms of target
interactions, peptides can occupy hydrophobic pockets favored
by small molecules and therefore provide an attractive means
for the discovery of druggable sites on proteins by acting as
probes or templates for pharmaceutical drugs. These applications
will see peptides becoming useful tools for target identification,
validation in addition to their use as therapeutics.
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